IMAGE: Tejas Patil, M.D., and colleagues show equal incidence of brain metastasis at time of diagnosis for stage IV ROS1, ALK, BRAF, EGFR and KRAS lung cancers. view more
Credit: University of Colorado Cancer Center
Increasingly, doctors are treating lung cancer based on the genetic rearrangements driving the disease. For example, cancers that are driven by changes in the genes ALK, EGFR, and ROS1 can now all be paired with drugs that target these specific changes. However, these cancers are not only dangerous in the lung where they appear, but can become especially dangerous if they are able to metastasize to the brain – a common cause of death from lung cancer. And some targeted treatments work better than others against cancer that has spread to the brain.
A University of Colorado Cancer Center study published in the Journal of Thoracic Oncology explores the occurrence and treatment of brain metastases in stage IV ROS1-positive non-small cell lung cancer. Importantly, and in contrast with the findings of previous groups, brain metastases were found to be fairly common in stage IV ROS1-positive cancers. In this study, 36 percent of 33 ROS1 patients (compared with 34 percent of 115 ALK patients) tested
Article originally posted at